Oak Therapeutics receives NIH/NIAID contract

October 1, 2016

We are proud to announce that we have received a contract from NIAID, the National Institute of Allergy and Infectious Diseases, a division of NIH, the National Institutes of Health. The contract enables us to develop a high-dose antibiotic Oral Dissolvable Strip (ODS) for children that is used in the treatment of tuberculosis. Tuberculosis (TB) is one of the world's deadliest diseases: Approximately one third of the world's population is infected with TB. In 2014, 9.6 million people around the world became sick with tuberculosis, and approximately 1.5 million people, many of them children, died. Our research and development will help the global fight against tuberculosis by improving patient adherence. Patients around the world have difficulties swallowing medication in the form of tablets and capsules, and they dislike the taste of difficult-to-handle liquid medications. Oral Dissolvable Strips (ODS) address all of these issues - they taste pleasantly, dissolve in the mouth without the need for water, and they work fast and effectively. 

Please reload

Featured Posts

All of us at Oak Therapeutics are extremely proud to announce that we just concluded initial preclinical testing of our anti-malarial medication Artel...


June 17, 2015

Please reload

Recent Posts
Please reload

Please reload

Search By Tags
Please reload

Follow Us
  • Facebook Basic Square
  • Twitter Basic Square
  • Google+ Basic Square

Oak Therapeutics, Inc., 2029 Becker Drive, Lawrence, KS 66047, United States, Tel. +1-913-346-0990, Email: office@oaktherapeutics.com